![Biotech venture firms continue ‘recalibration’ in third quarter, Pitchbook report finds](https://www.biopharmadive.com/imgproxy/RQrc3_6HGm9x7tNvAwS9yUMrwzX-VKqpKx2qPz5mTAE/g:ce/rs:fill:770:435:0/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTY3MzM3MTQzMC5qcGc.jpg)
Biotech venture firms continue ‘recalibration’ in third quarter, Pitchbook report finds
Dive Brief: Venture capital activity in biotechnology is undergoing a “recalibration towards pre-pandemic investment norms,” according to a new quarterly report from Pitchbook that tracks global funding and dealmaking in the sector. Pitchbook projects there will be about 840 venture deals totaling $24 billion by the end of the year, a steep decline from the…